相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2021)
Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study
Ann Vankerckhoven et al.
CELLS (2020)
Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy plus /- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
K. N. Moore et al.
ANNALS OF ONCOLOGY (2020)
A single-cell landscape of high-grade serous ovarian cancer
Benjamin Izar et al.
NATURE MEDICINE (2020)
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors
C. Landolfo et al.
GYNECOLOGIC ONCOLOGY (2020)
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Reem D. Mahmood et al.
CURRENT ONCOLOGY REPORTS (2020)
Combining conventional therapy with immunotherapy: A risky business?
A. Coosemans et al.
EUROPEAN JOURNAL OF CANCER (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors
An Coosemans et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients
Pauline L. de Goeje et al.
CLINICAL CANCER RESEARCH (2019)
Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
Kathleen N. Moore et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications
Aya S. Khairallah et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Allen W. Zhang et al.
CELL (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity
Orneala Bakos et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
Ignace Vergote et al.
LANCET ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antigen-specific active immunotherapy for ovarian cancer
Sterre T. Paijens et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Changes in regulatory T cells in patients with ovarian cancer undergoing surgery: Preliminary results
Meng Wu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients
Marek Nowak et al.
IMMUNOBIOLOGY (2017)
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
John S. Yi et al.
CLINICAL CANCER RESEARCH (2017)
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
Alejandro Jimenez-Sanchez et al.
CELL (2017)
Ovarian cancer and the immune system
Thais Baert et al.
GYNECOLOGIC ONCOLOGY REPORTS (2017)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions
A. Karam et al.
ANNALS OF ONCOLOGY (2017)
Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course
An Coosemans et al.
ONCOIMMUNOLOGY (2016)
Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer
Andreas Heindl et al.
ONCOTARGET (2016)
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
Sean Kehoe et al.
LANCET (2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Jaime Prat
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2014)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2013)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer EDITORIAL COMMENT
Robert A. Burger et al.
OBSTETRICAL & GYNECOLOGICAL SURVEY (2012)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
Xia Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125
Ben Van Calster et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer
S Coleman et al.
CANCER RESEARCH (2005)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
